Ervogastat/Clesacostat Fast Tracked for Nonalcoholic Steatohepatitis
The Food and Drug Administration (FDA) has granted Fast Track status to the combination of ervogastat and clesacostat for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. Ervogastat is a diacylglycerol O-acyltransferase 2 inhibitor…